142 related articles for article (PubMed ID: 32736891)
1. The effect of linagliptin on renal progression in type-2 diabetes mellitus patients with chronic kidney disease: A prospective randomized controlled study.
Yagoglu AI; Dizdar OS; Erdem S; Akcakaya B; Gunal AI
Nefrologia (Engl Ed); 2020; 40(6):664-671. PubMed ID: 32736891
[TBL] [Abstract][Full Text] [Related]
2. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA
Rosenstock J; Perkovic V; Alexander JH; Cooper ME; Marx N; Pencina MJ; Toto RD; Wanner C; Zinman B; Baanstra D; Pfarr E; Mattheus M; Broedl UC; Woerle HJ; George JT; von Eynatten M; McGuire DK;
Cardiovasc Diabetol; 2018 Mar; 17(1):39. PubMed ID: 29540217
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: A 40-week extension of the GUARD randomized study.
Han SY; Yoon SA; Han BG; Kim SG; Jo YI; Jeong KH; Oh KH; Park HC; Park SH; Kang SW; Na KR; Kang SW; Kim NH; Jang Y; Kim B; Shin S; Cha DR
Diabetes Obes Metab; 2018 Feb; 20(2):292-300. PubMed ID: 28719008
[TBL] [Abstract][Full Text] [Related]
4. Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial.
Perkovic V; Toto R; Cooper ME; Mann JFE; Rosenstock J; McGuire DK; Kahn SE; Marx N; Alexander JH; Zinman B; Pfarr E; Schnaidt S; Meinicke T; von Eynatten M; George JT; Johansen OE; Wanner C;
Diabetes Care; 2020 Aug; 43(8):1803-1812. PubMed ID: 32444457
[TBL] [Abstract][Full Text] [Related]
5. Linagliptin, when compared to placebo, improves CD34+ve endothelial progenitor cells in type 2 diabetes subjects with chronic kidney disease taking metformin and/or insulin: a randomized controlled trial.
Awal HB; Nandula SR; Domingues CC; Dore FJ; Kundu N; Brichacek B; Fakhri M; Elzarki A; Ahmadi N; Safai S; Fosso M; Amdur RL; Sen S
Cardiovasc Diabetol; 2020 Jun; 19(1):72. PubMed ID: 32493344
[TBL] [Abstract][Full Text] [Related]
6. Combination of the dipeptidyl peptidase-4 inhibitor linagliptin with insulin-based regimens in type 2 diabetes and chronic kidney disease.
McGill JB; Yki-Järvinen H; Crowe S; Woerle HJ; von Eynatten M
Diab Vasc Dis Res; 2015 Jul; 12(4):249-57. PubMed ID: 25941160
[TBL] [Abstract][Full Text] [Related]
7. DPP-4 inhibition has no acute effect on BNP and its N-terminal pro-hormone measured by commercial immune-assays. A randomized cross-over trial in patients with type 2 diabetes.
Fadini GP; Bonora BM; Albiero M; Zaninotto M; Plebani M; Avogaro A
Cardiovasc Diabetol; 2017 Feb; 16(1):22. PubMed ID: 28183314
[TBL] [Abstract][Full Text] [Related]
8. Concordance with prescribing information dosage recommendations for dipeptidyl-peptidase-4 inhibitors among type 2 diabetes mellitus patients with moderate to severe chronic kidney disease.
Huang H; Shetty S; Bauer E; Lang K
Curr Med Res Opin; 2018 Jun; 34(6):1021-1027. PubMed ID: 29231750
[TBL] [Abstract][Full Text] [Related]
9. Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes.
Cooper ME; Perkovic V; McGill JB; Groop PH; Wanner C; Rosenstock J; Hehnke U; Woerle HJ; von Eynatten M
Am J Kidney Dis; 2015 Sep; 66(3):441-9. PubMed ID: 25960304
[TBL] [Abstract][Full Text] [Related]
10. Dipeptidyl peptidase-4 inhibition in chronic kidney disease and potential for protection against diabetes-related renal injury.
Penno G; Garofolo M; Del Prato S
Nutr Metab Cardiovasc Dis; 2016 May; 26(5):361-73. PubMed ID: 27105869
[TBL] [Abstract][Full Text] [Related]
11. Acute Effects of Linagliptin on Progenitor Cells, Monocyte Phenotypes, and Soluble Mediators in Type 2 Diabetes.
Fadini GP; Bonora BM; Cappellari R; Menegazzo L; Vedovato M; Iori E; Marescotti MC; Albiero M; Avogaro A
J Clin Endocrinol Metab; 2016 Feb; 101(2):748-56. PubMed ID: 26695864
[TBL] [Abstract][Full Text] [Related]
12. Dipeptidyl peptidase-4 inhibitors and cardiovascular and renal disease in type 2 diabetes: What have we learned from the CARMELINA trial?
Hanssen NM; Jandeleit-Dahm KA
Diab Vasc Dis Res; 2019 Jul; 16(4):303-309. PubMed ID: 31018682
[TBL] [Abstract][Full Text] [Related]
13. Dipeptidyl peptidase-4 inhibition with linagliptin and effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: Rationale and design of the MARLINA-T2D™ trial.
Groop PH; Cooper ME; Perkovic V; Sharma K; Schernthaner G; Haneda M; Hocher B; Gordat M; Cescutti J; Woerle HJ; von Eynatten M
Diab Vasc Dis Res; 2015 Nov; 12(6):455-62. PubMed ID: 26224765
[TBL] [Abstract][Full Text] [Related]
14. Linagliptin in patients with type 2 diabetes and cardiovascular and/or renal disease: results from a cardiovascular and renal outcomes trial.
Guthrie R
Postgrad Med; 2020 May; 132(4):314-319. PubMed ID: 32164494
[TBL] [Abstract][Full Text] [Related]
15. Effect of Linagliptin on Cognitive Performance in Patients With Type 2 Diabetes and Cardiorenal Comorbidities: The CARMELINA Randomized Trial.
Biessels GJ; Verhagen C; Janssen J; van den Berg E; Zinman B; Rosenstock J; George JT; Passera A; Schnaidt S; Johansen OE;
Diabetes Care; 2019 Oct; 42(10):1930-1938. PubMed ID: 31399442
[TBL] [Abstract][Full Text] [Related]
16. Effects of the linagliptin, dipeptidyl peptidase-4 inhibitor, on bone fragility induced by type 2 diabetes mellitus in obese mice.
Kanda J; Furukawa M; Izumo N; Shimakura T; Yamamoto N; Takahashi HE; Wakabayashi H
Drug Discov Ther; 2020 Nov; 14(5):218-225. PubMed ID: 33116039
[TBL] [Abstract][Full Text] [Related]
17. The dipeptidyl peptidase inhibitor linagliptin and the angiotensin II receptor blocker telmisartan show renal benefit by different pathways in rats with 5/6 nephrectomy.
Tsuprykov O; Ando R; Reichetzeder C; von Websky K; Antonenko V; Sharkovska Y; Chaykovska L; Rahnenführer J; Hasan AA; Tammen H; Alter M; Klein T; Ueda S; Yamagishi SI; Okuda S; Hocher B
Kidney Int; 2016 May; 89(5):1049-1061. PubMed ID: 27083282
[TBL] [Abstract][Full Text] [Related]
18. Antiproteinuric effect of DPP-IV inhibitors in diabetic and non-diabetic kidney diseases.
Nicotera R; Casarella A; Longhitano E; Bolignano D; Andreucci M; De Sarro G; Cernaro V; Russo E; Coppolino G
Pharmacol Res; 2020 Sep; 159():105019. PubMed ID: 32553713
[TBL] [Abstract][Full Text] [Related]
19. The MARLINA-T2D trial: putting the results into clinical perspective.
Lajara R
Expert Rev Endocrinol Metab; 2018 May; 13(3):173-176. PubMed ID: 30058901
[TBL] [Abstract][Full Text] [Related]
20. Renal impairment has no clinically relevant effect on the long-term exposure of linagliptin in patients with type 2 diabetes.
Friedrich C; Emser A; Woerle HJ; Graefe-Mody U
Am J Ther; 2013; 20(6):618-21. PubMed ID: 23411609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
